P1.11.85 Overall Survival With Nivolumab Plus Relatlimab With Platinum-Doublet Chemotherapy in Metastatic NSCLC From RELATIVITY-104
L.G. Paz-Ares, M. Cobo-Dols, Mauricio Burotto, M. Schenker et autres
0 citationsJournal of Thoracic Oncology
M. Schenker
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
12Publications signalées
90Citations signalées
1Affiliations récentes
Institutions déclarées
Domaines associés
Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesLung Cancer Treatments and MutationsGenetic factors in colorectal cancerBrain Metastases and Treatment
Publications récentes
LBA29 Nivolumab plus ipilimumab vs nivolumab monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): New results from CheckMate 8HW
S. Lonardi, H.J. Lenz, E. Elez Fernandez, L.H. Jensen et autres
2 citationsAnnals of Oncology
1O Nivolumab (NIVO) plus ipilimumab (IPI) vs NIVO monotherapy for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Health-related quality of life (HRQoL) analyses from CheckMate 8HW
E. Elez Fernandez, T. André, S. Lonardi, H.J. Lenz et autres
0 citationsAnnals of Oncology
Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial
E. Felip, C.I. Rojas, M. Schenker, D.M. Kowalski et autres
38 citationsAnnals of Oncology
8MO: Subcutaneous (SC) versus intravenous (IV) pembrolizumab (Pembro) plus chemotherapy (CT) in metastatic non-small cell lung cancer (mNSCLC): Phase III MK-3475A-D77 trial
E. Felip, C.I. Rojas, M. Schenker, D.M. Kowalski et autres
0 citationsJournal of Thoracic Oncology
P051: Exploring the clinical utility of Oncotype DX in ER+/HER2-, N0 and N1 breast cancer patients: Insights from a Romanian cohort
Alexandru Blidaru, Daniela Zob, M. Schenker, Andrea Onisim et autres
0 citationsThe Breast
MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227
Makoto Nishio, S.S. Ramalingam, Tudor–Eliade Ciuleanu, R. Bernabe et autres
0 citationsAnnals of Oncology
LBA53 Nivolumab (NIVO) plus relatlimab with platinum-doublet chemotherapy (PDCT) vs NIVO + PDCT as first-line (1L) treatment (tx) for stage IV or recurrent NSCLC: Results from the randomized phase II RELATIVITY-104 study
N. Girard, Mauricio Burotto, L.G. Paz-Ares, Martin Reck et autres
21 citationsAnnals of Oncology
Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): first results of the CheckMate 8HW study
G. Folprecht, Thierry André, Elena Élez, Eric Van Cutsem et autres
14 citationsZeitschrift für Gastroenterologie
OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
S.S. Ramalingam, T-E. Ciuleanu, R. Bernabe, Makoto Nishio et autres
12 citationsJournal of Thoracic Oncology
41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC)
H. Borghaei, David Balli, L. Paz-Ares, M. Reck et autres
0 citationsJournal of Thoracic Oncology
1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
T. John, T-E. Ciuleanu, M. Cobo Dols, M. Schenker et autres
3 citationsAnnals of Oncology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.